Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 12
Submit an article Journal homepage
311
Views
28
CrossRef citations to date
0
Altmetric
Original Article: Research

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma

Raymond I. Cruz Departments of Medicine; Immunology
,
Francisco J. Hernandez-Ilizaliturri Departments of Medicine; Immunology
,
Scott Olejniczak Immunology
,
George Deeb Pathology
,
Joy Knight Immunology
,
Paul Wallace Flow Cytometry, Roswell Park Cancer Institute, Buffalo, NY, USA
,
Beth L. Thurberg Genzyme Corp., Framingham, MA, USA
,
William Kennedy Genzyme Corp., Framingham, MA, USA
&
Myron S. Czuczman Departments of Medicine; ImmunologyCorrespondence[email protected]
 show all
Pages 2424-2436 | Received 27 Jun 2007, Accepted 23 Aug 2007, Published online: 01 Jul 2009

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Tri-Hung Nguyen, Evis Havari, Rajashree McLaren, Mindy Zhang, Yide Jiang, Stephen L. Madden, Bruce Roberts, Johanne Kaplan & Srinivas Shankara. (2012) Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes. Leukemia & Lymphoma 53:4, pages 699-709.
Read now
Stephen J. Demarest, Kandasamy Hariharan & Jianying Dong. (2011) Emerging antibody combinations in oncology. mAbs 3:4, pages 338-351.
Read now
Jun Ho Yi, Seok Jin Kim, Young Hyeh Ko & Won Seog Kim. (2011) Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leukemia & Lymphoma 52:2, pages 317-320.
Read now
Carmen Diana Schweighofer & Clemens-Martin Wendtner. (2010) First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. OncoTargets and Therapy 3, pages 53-67.
Read now
William M. Siders, Jacqueline Shields, Carrie Garron, Yanping Hu, Paula Boutin, Srinivas Shankara, William Weber, Bruce Roberts & Johanne M. Kaplan. (2010) Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leukemia & Lymphoma 51:7, pages 1293-1304.
Read now
Lina Reslan, Stéphane Dalle & Charles Dumontet. (2009) Understanding and circumventing resistance to anticancer monoclonal antibodies. mAbs 1:3, pages 222-229.
Read now
Claudia Stolz & Martin Schuler. (2009) Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leukemia & Lymphoma 50:6, pages 873-885.
Read now

Articles from other publishers (21)

Kartik Bhamidipati, John L. Silberstein, Yashaar Chaichian, Matthew C. Baker, Tobias V. Lanz, Amin Zia, Yusuf S. Rasheed, Jennifer R. Cochran & William H. Robinson. (2021) CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function. Frontiers in Immunology 11.
Crossref
Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak & Grzegorz K. Przybylski. (2020) Novel targeted therapies of T cell lymphomas. Journal of Hematology & Oncology 13:1.
Crossref
Jinichi Mori, Kumi Oshima, Satoshi Kimura & Takayuki Ikezoe. (2020) Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology 2020, pages 1-4.
Crossref
Masayuki Wada, Hongyu Zhang, Liu Fang, Jia Feng, Charlotte Olivia Tse, Wenli Zhang, Qi Chen, Sha Sha, Yuanzhen Cao, Kevin H. Chen, Kevin G. Pinz, Xi Chen, Xing-Xing Fan, Xun Jiang & Yupo Ma. (2020) Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies. Stem Cell Reviews and Reports 16:2, pages 369-384.
Crossref
Akihiro Tomita. (2016) Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. Journal of Clinical and Experimental Hematopathology 56:2, pages 89-99.
Crossref
Jing Ai & Anjali Advani. (2015) Current status of antibody therapy in ALL. British Journal of Haematology 168:4, pages 471-480.
Crossref
Samith T. Kochuparambil & Mark R. Litzow. (2014) Novel Antibody Therapy in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 9:2, pages 165-173.
Crossref
Naval Daver & Susan O’Brien. (2013) Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies. Current Hematologic Malignancy Reports 8:2, pages 123-131.
Crossref
Yao Jiang, Yingchao Zhao, Xiaorong Dong, Sheng Zhang, Yan Li & Gang Wu. (2013) Loss of CD20 expression in relapsed diffuse large B cell lymphoma after rituximab therapy: a case report and review of the literature. The Chinese-German Journal of Clinical Oncology 12:3, pages 148-151.
Crossref
Ping-Chiao Tsai, Francisco J. Hernandez-Ilizaliturri, Naveen Bangia, Scott H. Olejniczak & Myron S. Czuczman. (2012) Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research 18:4, pages 1039-1050.
Crossref
Matthew J. Barth, Francisco J. Hernandez-Ilizaliturri, Cory Mavis, Ping-Chiao Tsai, John F. Gibbs, George Deeb & Myron S. Czuczman. (2012) Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology 156:4, pages 490-498.
Crossref
Nina A. Daha, Nirmal K. Banda, Anja Roos, Frank J. Beurskens, Joost M. Bakker, Mohamed R. Daha & Leendert A. Trouw. (2011) Complement activation by (auto-) antibodies. Molecular Immunology 48:14, pages 1656-1665.
Crossref
Wei Xu, Kou‐Rong Miao, Dan‐Xia Zhu, Cheng Fang, Hua‐Yuan Zhu, Hua‐Jie Dong, Dong‐Mei Wang, Yu‐Jie Wu, Chun Qiao & Jian‐Yong Li. (2011) Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. International Journal of Cancer 128:9, pages 2192-2201.
Crossref
Tomoaki Nakagawa, Akito Natsume, Mitsuo Satoh & Rinpei Niwa. (2010) Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils. Leukemia Research 34:5, pages 666-671.
Crossref
Wasif Riaz, Francisco J. Hernandez-Ilizaliturri & Myron S. Czuczman. (2009) Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic Research 46:1-3, pages 192-205.
Crossref
Yanping Hu, Michael J. Turner, Jacqueline Shields, Matthew S. Gale, Elizabeth Hutto, Bruce L. Roberts, William M. Siders & Johanne M. Kaplan. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128:2, pages 260-270.
Crossref
Deborah A. Thomas, Susan O'Brien & Hagop M. Kantarjian. (2009) Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, pages 949-971.
Crossref
Junji HiragaAkihiro TomitaTakumi SugimotoKazuyuki ShimadaMasafumi ItoShigeo Nakamura, Hitoshi Kiyoi, Tomohiro KinoshitaTomoki Naoe. (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:20, pages 4885-4893.
Crossref
Rogier M. Thurlings, Koen Vos, Daniëlle M. Gerlag & Paul P. Tak. (2008) Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders. Arthritis & Rheumatism 58:12, pages 3657-3664.
Crossref
Stefan Peinert & John F. Seymour. (2008) Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas. Hematology/Oncology Clinics of North America 22:5, pages 903-940.
Crossref
Xuhui Zhou, Weiguo Hu & Xuebin Qin. (2008) The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy. The Oncologist 13:9, pages 954-966.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.